Alfasigma participates in CPhI 2021, at the Milan Fair from 9 to 11 November to present all its news in the field of pharmaceutical development and production for third parties (contract development and contract manufacturing). CPhI is one of the most important trade fairs for the pharmaceutical industry and in particular for the settore contract development e contract manufacturing (cdmo) hosting thousands of industry professionals from all over the globe every year.
According to the most recent analysis by Grand view research, the size of the global contract manufacturing and contract development market in the healthcare market was valued at $ 204.8 billion in 2020 and is expected to expand at a compound annual growth rate ( cagr) of 8.6% from 2021 to 2028. This growth should be driven by a greater diffusion of outsourcing services by pharmaceutical companies and by the growth of investments in research and development. Medical device companies and pharmaceutical companies are outsourcing low-end services to reduce the overall cost of manufacturing and this trend is expected to contribute to the growth of the contract development and contract manufacturing (cdmo) market over the period indicated.
The participation in CPhI of Alfasigma fits into this framework, which for years has been one of the Italian leaders in the contract manufacturing sector (cdmo), providing a 360 ° integrated service in the pharmaceutical outsourcing activity for third party production in all pharmaceutical forms.
“Customer care and continuous support throughout the relationship with the customer, flexibility, as well as excellent production capacities assisted by technical support made up of know-how and cutting-edge technologies are the strong points of Alfasigma’s cdmo” says Eugenio Starita at the head of the cdmo division of Alfasigma.
With a 33% growth in items produced in the last year compared to 2018, Alfasigma in 2020 has produced nearly 70 million products divided into different pharmaceutical forms: injectable liquids, topicals, sterile powders, oral solids, injectable syringe vials and lyophilized products. The aforementioned analysis by Grand view research also underlines the increasing demand from companies across the sector for qualified scientists and project managers who are attentive to customer care.
“For this reason – continues Starita – the Alfasigma cdmo deals with customer care at 360 ° from business development with the identification of target market segments and the scouting of new opportunities, to customer service, passing through business analytics and project management design and planning as well as the evaluation of the technical feasibility of projects. Pharmaceutical production for third parties is carried out with high quality standards and maximum reliability, always guaranteed by the know-how achieved through years of experience, by the use of innovative technology and by a state-of-the-art pharmaceutical plant, recently expanded and enhanced “.
In fact, in recent years Alfasigma has started a important investment plan and expansion of the production plants in Pomezia and Alanno. The inauguration of the LABIO 4.0 Marino Golinelli for third-party development projects was recently celebrated in Pomezia and the Soft-gel department was opened and will become fully operational in 2022.
In Alanno, the production of injectables saw the construction of an aseptic area consisting of two new plants approved by Aifa: the Sterile 3 and the Sterile 4 which are spread over 1050 m2. The Sterile 3 department is dedicated to the filling of sterile powders / liquids, while the Sterile 4 department reflects the requirements of industry 4.0 and is strategic in terms of company business.
Inside there is an open Rabs classified filling machine capable of processing both pre-filled syringes and bottles (ready to use) thanks to the use of latest generation robots and manipulators with high technological content.